NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Abvc BioPharma, Inc. ABVC
16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$296,000
▼ 41.9% vs FY2024
EPS · FY25
$-0.39
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-128.2%
Net margin · FY25
-2671.8%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 296,000.00
Revenue, FY2025 · full 16-year series below
Revenue
Net income
The company lost 2672 cents on every revenue dollar this year.
Per share
USD -0.39
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-128.2%
Return on equity, FY2025
ROE
Operating margin-2416.0%
Net margin-2671.8%
Return on assets-55.3%
Each USD of equity lost 128 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−9.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−32.7%
−9.3%
−40.1%
+22.1%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.03B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 21.1M
total assets, end of FY2025
Total assetsUSD 21.1M
EquityUSD 11.1M
CashUSD 681,480.00
Gross debtUSD 755,512.00
Net debtUSD 74,032.00
Current ratio0.41×
Net debt stands at 1% of equity.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
0.1
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
·
·
·
·
·
Income tax $B
0.0
−0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
0.0
0.0
·
·
0.0
0.0
0.0
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.39
−0.42
−1.80
−5.19
−0.51
−0.50
−0.21
−0.48
−0.02
−0.06
−0.01
−0.01
0.00
−0.04
−0.31
−0.47
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−128.2
−352.7
−334.8
−275.0
−209.1
−644.5
·
·
·
·
−9.7
·
·
·
·
·
Shares out B
0.03
0.01
0.01
0.00
0.02
0.02
0.02
0.01
0.21
0.21
0.17
0.00
0.05
0.01
0.01
0.03
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
56 of 56
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed